Sudeep Pharma IPO Analyzed
Sudeep Pharma, a company making ingredients for medicines, food, and supplements, is holding an Initial Public Offering (IPO). Investors showed strong interest, bidding for 99,00,86,575 shares when the company offered 1,05,64,926. This means the IPO was hugely successful, subscribed 93.71 times. The IPO aims to raise up to Rs 800 crore, with a price range of Rs 563 to Rs 593 per share.
Key Points
- Huge investor interest: IPO subscribed 93.71 times.
- Price range: Rs 563 to Rs 593 per share.
- Raised Rs 268.49 crore from anchor investors.
- Funds for machines and general corporate purposes.
- Key products: Mineral salts, micronutrient systems.
- Company focuses on India & international exports.
The money raised will be used for building a new factory and for other business expenses. The company’s biggest shareholders – Sujit Jaysukh Bhayani and others – will sell some of their shares in this IPO. These shareholders already own a large chunk of the company, about 89.36% of the stock.
Sudeep Pharma makes ingredients for various industries. They produce things like calcium, zinc, and iron – these are crucial for making medicines and supplements. They also develop specialized ingredients for things like baby food and energy drinks.
In the last quarter, the company’s revenue was Rs 124.92 crore. Their profits were Rs 30.81 crore. This shows a strong business foundation, supported by sales primarily within India (41.32%) and international markets (58.68%).
Ahead of the IPO, the company secured funding from 25 major investors through an ‘anchor’ investment program. This pre-IPO investment provides a good indication of investor confidence and helps the company reach its fundraising goals.
Ultimately, a successful IPO signifies growing investor confidence in Sudeep Pharma’s future growth prospects.
